替罗非班在急性缺血性脑卒中的应用进展
Progress in the Application of Tirofiban in Acute Ischemic Stroke
摘要: 据统计我国缺血性脑卒中的治疗仍以抗血小板聚集为主，但多数此类病人急性期存在饮水呛咳，抗血小板聚集药物口服困难，早期静脉给予抗血小板药物(GP) IIb/IIIa受体拮抗剂具有重要的临床意义。以替罗非班为代表的(GP) IIb/IIIa受体拮抗剂起效快，半衰期较短，停止用药后血小板功能能迅速恢复，此药在心脏疾病方面的应用中已相对成熟，大量的研究已经证实了其治疗心脏疾病的有效性及安全性。然而替罗非班用于缺血性脑卒中治疗的相关研究及临床经验较匮乏，本文主要通过归纳替罗非班在缺血性脑卒中方面的应用，阐述替罗非班在急性缺血性脑卒中的临床价值，为后期脑梗死的治疗提供理论依据。
Abstract: According to statistics, the treatment of ischemic stroke in China is still mainly on platelet aggregation, but most of these patients have difficulty in drinking water and oral administration of anti-platelet aggregation drugs in the acute stage, and early intravenous administration of anti-platelet drug (GP) IIb/IIIa receptor antagonist has important clinical significance. However, the (GP) IIb/IIIa receptor antagonist represented by tirofiban has fast onset and short half-life, and the platelet function can be rapidly recovered after discontinuation of medication. This drug has been relatively mature in the application of heart disease, and a large number of studies have confirmed its effectiveness and safety in the treatment of heart disease. However, the related research and clinical experience of tirofiban in the treatment of ischemic stroke are relatively scarce. This paper mainly summarized the application of tirofiban in ischemic stroke, elaborated the clinical value of tirofiban in acute ischemic stroke, and provided a theoretical basis for the treatment of later cerebral infarction.
文章引用：冯鑫慧. 替罗非班在急性缺血性脑卒中的应用进展[J]. 临床医学进展, 2021, 11(11): 5413-5419. https://doi.org/10.12677/ACM.2021.1111800

参考文献

[1] Dornbos, D., Katz, J.S., Youssef, P., et al. (2018) Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications during Endovascular Embolization of Intracranial Aneurysms. Neurosurgery, 82, 268-277. [Google Scholar] [CrossRef] [PubMed]
[2] Hao, Z.L., Li, W., et al. (2011) Basic Characteristics and Functional Outcomes of Consecutive 3123 Patients in Chengdu Stroke Registry. Chinese Journal of Neurology, 44, 826-831.
[3] Wang, Z., Li, J., Wang, C., et al. (2013) Gender Differences in 1-Year Clinical Characteristics and Outcomes after Stroke: Results from the China National Stroke Registry. PLoS ONE, 8, e56459. [Google Scholar] [CrossRef] [PubMed]
[4] Siegler, J.E. and Martinschild, S. (2016) Intravenous Thrombolysis Attenuates Neurologic Deterioration after Ischemic Stroke. Southern Medical Journal, 109, 661-667. [Google Scholar] [CrossRef] 
[5] Siebler, M., Hennerici, M.G., Schneider, D., et al. (2011) Safety of Tirofiban in Acute Ischemic Stroke: The SaTIS Trial. Stroke, 42, 2388-2392. [Google Scholar] [CrossRef] 
[6] Baxter Healthcare Corporation (2019) AGGRASTAT® (tirofiban hydro_x0002_chloride) Injection, for Intravenous Use.
[7] Torgano, G., Zecca, B., Monzani, V., Maestroni, A., Rossi, P., Cazzaniga, M., Manganaro, D., Boiti, C., Zilioli, E., Borutti, G., Falaschi, F. and Mandelli, C. (2010) Effect of Intravenous Tirofiban and Aspirin in Reducing Short-Term and Long-Term Neurologic Deficit in Patients with Ischemic Stroke: A Double-Blind Randomized Trial. Cerebrovascular Diseases, 29, 275-281. [Google Scholar] [CrossRef] [PubMed]
[8] Seitz, R.J., Hamzavi, M., Junghans, U., Ringleb, P.A., Schranz, C. and Siebler, M. (2003) Thrombolysis with Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations. Stroke, 34, 1932-1935. [Google Scholar] [CrossRef] 
[9] Junghans, U., Seitz, R.J., Aulich, A., Freund, H.J. and Siebler, M. (2001) Bleeding Risk of Tirofiban, a Nonpeptide GP IIb/IIIa Platelet Receptor Antagonist in Progressive Stroke: An Open Pilot Study. Cerebrovascular Diseases, 12, 308-312. [Google Scholar] [CrossRef] [PubMed]
[10] 冯学问, 陈智才, 钟根龙, 等. 急性缺血性卒中患者血管内治疗后应用替罗非班的安全性及预后分析[J]. 浙江大学学报(医学版), 2017, 46(4): 397-404.
[11] Seo, J.H., Jeong, H.W., Kim, S.T., et al. (2015) Adjuvant Tirofiban Injection through Deployed Solitaire Stent as a Rescue Technique after Failed Mechanical Thrombectomy in Acute Stroke. Neurointervention, 10, 22-27. [Google Scholar] [CrossRef] [PubMed]
[12] Saqqur, M., Molina, C.A., Salam, A., et al. (2007) Clinical Deterioration after Intravenou Recombinant Tissue Plasminogen Activator Treatment: A Multicenter Transcranial Doppler Study. Stroke, 38, 69-74. [Google Scholar] [CrossRef] 
[13] Gong, J., Shang, J., Yu, H., Wan, Q., Su, D., Sun, Z. and Liu, G. (2020) Tirofiban for Acute Ischemic Stroke: Systematic Review and Meta-Analysis. European Journal of Clinical Pharmacology, 76, 475-481. [Google Scholar] [CrossRef] [PubMed]
[14] 赵明明, 富奇志. 替罗非班联合抗血小板药物治疗短暂性脑缺血发作的临床效果观察[J]. 临床合理用药杂志, 2020, 13(8): 31-32.
[15] Liu, J., Shi, Q., Sun, Y., He, J., Yang, B., Zhang, C. and Guo, R. (2019) Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 28, 1126-1132. [Google Scholar] [CrossRef] [PubMed]
[16] Wu, C., Sun, C., Wang, L., Lian, Y., Xie, N., Huang, S., Zhao, W., Ren, M., Wu, D., Ding, J., Song, H., Wang, Y., Ma, Q. and Ji, X. (2019) Low-Dose Tirofiban Treatment Improves Neurological Deterioration Outcome after Intravenous Thrombolysis. Stroke, 50, 3481-3487. [Google Scholar] [CrossRef] 
[17] Liu, B., Zhang, H., Wang, R., Qu, H., Sun, Y., Zhang, W. and Zhang, S. (2020) Early Administration of Tirofiban after Urokinase-Mediated Intravenous Thrombolysis Reduces Early Neurological Deterioration in Patients with Branch Atheromatous Disease. Journal of International Medical Research, 48, 300060520926298. [Google Scholar] [CrossRef] [PubMed]
[18] 周星辰, 束汉生, 王大巍, 张辉, 王昊, 杨光, 闵敬亮. 替罗非班在超时间窗非大血管闭塞性缺血性卒中中的应用价值[J]. 中国现代神经疾病杂志, 2020, 20(8): 740-745.
[19] Fu, Z., Xu, C., Liu, X., Wang, Z. and Gao, L. (2020) Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Meta-Analysis. Cerebrovascular Diseases, 49, 442-450. [Google Scholar] [CrossRef] [PubMed]
[20] Yang, J., Wu, Y., Gao, X., Bivard, A., Levi, C.R., Parsons, M.W., Lin, L. and INSPIRE Study Group (2020) Intraarterial versus Intravenous Tirofiban as an Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke. Stroke, 51, 2925-2933. [Google Scholar] [CrossRef] 
[21] Zhang, S., Hao, Y., Tian, X., Zi, W., Wang, H., Yang, D., Zhang, M., Zhang, X., Bai, Y., Li, Z., Sun, B., Li, S., Fan, X., Liu, X. and Xu, G. (2019) Safety of Intra-Arterial Tirofiban Administration in Ischemic Stroke Patients after Unsuccessful Mechanical Thrombectomy. Journal of Vascular and Interventional Radiology, 30, 141-147.e1. [Google Scholar] [CrossRef] [PubMed]
[22] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组, 中华医学会神经病学分会神经血管介入协作组. 中国缺血性脑血管病血管内介入诊疗指南2015[J]. 中华神经科杂志, 2015, 48(10): 830-837.
[23] 症状性颅内动脉粥样硬化性狭窄血管内治疗专家共识组. 症状性颅内动粥样硬化性狭窄血管内治疗中国专家共识[J]. 中华内科杂志, 2013, 52(3): 371-375.
[24] 王育斌, 刘佩军. 替罗非班在颅内动脉狭窄支架置入术中的应用[J]. 湖北科技学院学报(医学版), 2012, 26(5): 388-391.
[25] Zahn, R., Ischinger, T., Hochadel, M., et al. (2007) Glycoprotein IIb/IIIa Antagonists during Carotid Artery Stenting: Results from the Carotid Artery Stenting (CAS) Registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Clinical Research in Cardiology, 96, 730-737. [Google Scholar] [CrossRef] [PubMed]
[26] Van Dellen, D., Tiivas, C.A., Jarvi, K., et al. (2008) Transcranial Doppler Ultrasonography-Directed Intravenous Glycoprotein IIb/IIIa Receptor Antagonist Therapy to Control Transient Cerebral Microemboli before and after Carotid Endarterectomy. British Journal of Surgery, 95, 709-713. [Google Scholar] [CrossRef] [PubMed]
[27] Wholey, M.H., Wholey, M.H., Eles, G., et al. (2003) Evaluation of Glycoprotein IIb/IIIa Inhibitors in Carotid Angioplasty and Stenting. Journal of Endovascular Therapy, 10, 33-41. [Google Scholar] [CrossRef] [PubMed]
[28] Huo, X., Wang, A., Mo, D., Gao, F., Ma, N., Wang, Y., Wang, Y. and Miao, Z. (2021) Safety and Efficacy of Tirofiban for Acute Ischemic Stroke Patients with Large Artery Atherosclerosis Stroke Etiology Undergoing Endovascular Therapy. Frontiers in Neurology, 12, Article ID: 630301. [Google Scholar] [CrossRef] [PubMed]
[29] 刘丽萍, 陈玮琪, 段婉莹, 等. 中国脑血管病临床管理指南(节选版)——缺血性脑血管病临床管理[J]. 中国卒中杂志, 2019, 14(7): 709-726.
[30] 中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2018[J]. 中国卒中杂志, 2018, 13(7): 706-729.

为你推荐